Your browser doesn't support javascript.
loading
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby, Alaa; Kutzera, Joachim; Geenen, Jill J; Pluim, Dick; Hofland, Ingrid; Sanders, Joyce; Lopez-Yurda, Marta; Beijnen, Jos H; Huitema, Alwin D R; Witteveen, Petronella O; Steeghs, Neeltje; van Haaften, Gijs; van Vugt, Marcel A T M; de Ridder, Jeroen; Opdam, Frans L.
Afiliação
  • Embaby A; Department of Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. Electronic address: a.embaby@nki.nl.
  • Kutzera J; Department of Genetics, Utrecht University, Utrecht, the Netherlands.
  • Geenen JJ; Department of Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Pluim D; Department of Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Hofland I; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Sanders J; Department of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Lopez-Yurda M; Biometrics Department, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Beijnen JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Huitema ADR; Department of Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrech
  • Witteveen PO; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • van Haaften G; Department of Genetics, Utrecht University, Utrecht, the Netherlands.
  • van Vugt MATM; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
  • de Ridder J; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Opdam FL; Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Gynecol Oncol ; 174: 239-246, 2023 07.
Article em En | MEDLINE | ID: mdl-37236033
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article